Nitin Jain, M.D., is a Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas, USA. He earned his medical degree from the All India Institute of Medical Sciences (AIIMS), New Delhi, India in 2002. He completed Internal Medicine residency at the Medical College of Wisconsin, Milwaukee. He then completed clinical fellowship in Leukemia at MD Anderson followed by a Leukemia research fellowship at Memorial Sloan-Kettering Cancer Center. He then pursued fellowship in Hematology/Oncology at The University of Chicago. He joined as a faculty in the Department of Leukemia at MD Anderson in July 2012. Dr. Jain treats patients with acute and chronic leukemias with focus of patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). Dr. Jain's research interests focus on new drug development for patients with leukemia, especially CLL and ALL. Since 2021, he has also served as Director, Leukemia CAR-T Program within the Department of Leukemia, MD Anderson.
Dr. Jain is Principal Investigator of several investigator-initiated phase I-II clinical trials, including combination targeted therapies (ibrutinib and venetoclax) in CLL, checkpoint inhibitor in Richter transformation, JAK2 inhibitor ruxolitinib in Ph-like ALL, novel CD22 antibody drug conjugate in B-ALL, venetoclax + chemotherapy in B- and T-ALL, ponatinib in T-ALL, and off-the-self allogeneic CARTs in B-ALL. The trial combining ibrutinib and venetoclax was published in New England Journal of Medicine in 2019. He has published papers in prominent journals including NEJM, Lancet, JAMA Oncology, Journal of Clinical Oncology, Blood, Clinical Cancer Research, Cancer, Leukemia & Lymphoma, and others.